retatrutide clinical trial results safety Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide Phase 3 Results: Trials,
Description
Learn about treatment options, lab testing, and personalized metabolic support plans.
However, we may receive compensation from retailers and/or from purchases of prod
Physician-supervised GLP-1 weight loss with personalized dosing, telehealth visits & home delivery
TOTAL STRENGTH: 30 mg per box
Retatrutide is a next-generation synthetic peptide acting as a triple receptor agonist, simultaneously targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
It plays a key role in regulating GLP-1 production, helping to control appetite and support natural weight management
